Market Overview

Needham Says Buy the Dip in Isis Pharma, Didn't See Favorable Chance CRP Would Be Indicated for RA

Share:
Related ISIS
Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOr Cardiovascular, Metabolic And Renal Disease
AstraZeneca, Isis Pharmaceuticals to Collaborate to Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases
Isis Pharmaceuticals (ISIS) Misses Earnings Estimates in Q2 - Tale of the Tape (Zacks)

Shares of Isis Pharma (NASDAQ: ISIS) have fallen nearly 3 percent Monday as the company announced it has halted development of its rheumatoid arthritis product as the latest study failed to demonstrate a benefit.

Needham analyst Chad Messer issued a research note earlier suggesting investors should use the dip in price to load up on shares. Messer pointed out he didn't consider the RA drug as a "serious consideration" for the company's ISIS-CRP. He believes the next catalyst for APOCIII monotherapy trial is later in August.

Needham maintains a Buy rating and $36 price target on shares of Isis Pharma.

Latest Ratings for ISIS

DateFirmActionFromTo
Jun 2015NeedhamReiteratesBuy
Jun 2015JP MorganMaintainsNeutral
Mar 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (ISIS)

Get Benzinga's Newsletters